{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4L6iyOgJDA","lastupdate":"2022-08-29T00:00:00.000Z","update_date":"2022-08-29T00:00:00.000Z","lastModified":"Apr 3, 2025","active":1,"confidence_score":99,"confidence_score_reason":"markets","urlname":"prilenia-therapeutics","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$iBDdqS5peD0NxCANlMyQe0kfRmkIp3vXnBbMTgddyAf25zpK173jEG","name":"Prilenia Therapeutics","oneliner":"Developing New Treatments for Neurodegenerative Diseases","registrar":"515842854","website":"https://prilenia.com","careerspage":"https://prilenia.comjoin-us/","founded_month":5,"founded_year":2018,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/PrileniaTx","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/26568559","instagram":""},"social":["https://www.linkedin.com/company/26568559","https://twitter.com/PrileniaTx"],"flattenedsociallinks":"https://www.linkedin.com/company/26568559|https://twitter.com/PrileniaTx","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":56,"patent":1,"raised":144500000,"stage":"B","public_stage":"B","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Prilenia is a late clinical-stage biotechnology company founded in 2018 focused on the urgent mission to develop novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders. The initial focus of the company has been on Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). ​\n\nPrilenia's lead compound is pridopidine (45 mg twice daily), a first-in-class, oral, highly selective and potent investigational S1R agonist that is in pre-registration for HD and Phase 3-stage development for ALS. Prilenia holds Orphan Drug designation for pridopidine in HD and ALS in the U.S. and EU. In addition, pridopidine has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD.​\n\nPrilenia is backed by a group of well-respected investors including: Forbion, Morningside, Sands Capital, SV Health Investors, Sectoral Asset Management, Talisman, Amplitude Ventures and the ALS Investment Fund. ​","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972775558482","country":null,"address":{"israeli":[{"id":"hnJu1kMkGfw13mJ6HN5nG54CumwHPZKgIInrUdEHqyOrW5Pl1AiV6v","city":"Yakum","type":null,"address":"Yakum, Israel","placeid":"ChIJd4p-9EpHHRURLfcDOj3SYn8","notactive":null,"openeddate":null,"registrarid":null,"firstrdcenter":null,"registrarname":null}],"officesabroad":[{"id":"d291b6a3-e1bd-4309-b379-0463df369f9e","city":"Naarden","address":"Naarden, Netherlands","country":"Netherlands","placeid":null},{"id":"f6qT9Vk5YQkx3r6MtK3ZiZsZLG1FPVy2xEInYj9F1LwljATlBnap7b","city":"Waltham","address":"Waltham, MA, USA","country":"United States","placeid":"ChIJ3eQad-F344kRxFr-GmKH2t4"}]},"headquarter_address":null,"district":null,"news":[{"id":"05X95GMaybdbvKQrihu4FnSHk7AhBqvrPKGiT4mgwNUlIRAGZ79H0k","date":"Mar 19, 2024","link":"https://huntingtonsdiseasenews.com/news/prilenia-will-seek-european-approval-pridopidine-huntingtons/","source":"huntingtonsdiseasenews.com","visible":1,"analysis":{"tags":"Drug Approval, Huntingtons Disease Treatment","company":"Prilenia Therapeutics","layoffs":"Not mentioned","summary":"Prilenia Therapeutics is planning to submit a marketing authorization application (MAA) for the approval of pridopidine, a treatment for Huntingtons disease, in the European Union. The filing follows positive discussions at pre-submission meetings with the Committee for Medicinal Products for Human Use, part of the European Medicines Agency (EMA). If approved, the therapy could be available to patients as early as 2025. Prilenia also plans to discuss potential approval in the U.S. with the Food and Drug Administration and consider filing for approval in other countries following the EMAs review.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Drug Approval","Huntingtons Disease","Pridopidine","Clinical Trials","EMA Submission"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"4gP7GKJO2WO1Jfn0bMpTkyVjfp54rQHvgcx9Zt1NOSWI8vBM4q0k40","news_summary":"Prilenia to seek European approval of pridopidine for Huntington's","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"VOJ26gNQ3wvYIxDbXToOwip4rh3FS47r3xNCeXHqCn1WXnGiV510m2","date":"Jan 19, 2024","link":"https://www.businesswire.com/news/home/20240118053094/en/Prilenia-Announces-Clinical-Data-in-Support-of-its-Plans-to-Initiate-Global-Phase-3-Study-in-ALS","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Drug Development","company":"Prilenia Therapeutics B.V.","layoffs":"N/A","summary":"Prilenia Therapeutics B.V., a clinical stage biotechnology company, is planning to start a pivotal Phase 3 study in H2 2024 for the development of pridopidine, a potential treatment for amyotrophic lateral sclerosis (ALS) and Huntington’s disease. The company has completed discussions with global regulatory agencies regarding the next stage of development of pridopidine for ALS. The company is backed by a group of investors including Forbion, Morningside, Sands Capital, SV Health Investors, Sectoral Asset Management, Talisman, Amplitude Ventures and the ALS Investment Fund.","partners":["Massachusetts General Hospital","Healey Center","National Institutes of Health (NIH)"],"customers":"N/A","investors":["Forbion","Morningside","Sands Capital","SV Health Investors","Sectoral Asset Management","Talisman","Amplitude Ventures","ALS Investment Fund"],"confidence":8,"key_topics":["ALS Treatment","Clinical Data","Phase 3 Study","Pridopidine","Investors"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5AhP2FzSvHRNtJGWhOZshhXjzXykujyYrj1oXK0p4CYzbElFz4eg5j","news_summary":"Prilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"T9EQEV9gGazlTxXMFQykS6NxU65D7qZc5AdUmWmXftEvo2tIxsmpU9","date":"Oct 10, 2023","link":"https://alsnewstoday.com/news/nih-grant-supports-als-expanded-access-program-pridopidine/","source":"alsnewstoday.com","visible":1,"analysis":{"tags":"Clinical Trials, ALS Treatment","company":"Prilenia Therapeutics","layoffs":"Not mentioned","summary":"Prilenia Therapeutics is set to provide its experimental ALS treatment, pridopidine, to patients not eligible for clinical trials through an expanded access program (EAP). The EAP, funded by a grant from the National Institute of Neurological Disorders and Stroke and supported by the Accelerating Access to Critical Therapies for ALS act, will enroll about 200 patients across 45 centers in the U.S. The program will provide real-world safety, biomarker, and clinical data on the effects of pridopidine in a broad population. Despite failing to meet its primary goal in Phase 2/3 trials, pridopidine showed significant benefits in certain speech measures and positive trends in respiratory function.","partners":"Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital","customers":"ALS patients","investors":"National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)","confidence":8,"key_topics":["ALS","Pridopidine","Clinical Trials","Expanded Access Program","Research"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"djcb7Ot3HgXpR9ljXDgTxOkQ5l8rVnhPMQwnwHFStwnAfBM92KlDxD","news_summary":"New EAP will allow pridopidine use for ALS patients not in trial |...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"KrqoZBEj6g8AGxtsXqK14rKH2PBjlO99Lm7ImI3Ip9D9VcqQN9KIAz","date":"May 25, 2022","link":"https://www.newswise.com/articles/prilenia-announces-publication-of-data-elucidating-a-mechanism-for-neuroprotective-potential-of-pridopidine","source":"www.newswise.com","visible":1,"analysis":{"tags":["neurodegenerative diseases","neuroprotective properties","pridopidine","autophagy","ALS","Huntingtons disease"],"company":"Prilenia Therapeutics B.V.","layoffs":null,"summary":"Prilenia Therapeutics B.V. has published research in the peer-reviewed journal Autophagy, highlighting the potential neuroprotective properties of pridopidine in an amyotrophic lateral sclerosis (ALS) model. Pridopidine, an oral Sigma-1 Receptor agonist, is currently in late-stage development for the treatment of Huntingtons disease (HD) and ALS. The research shows that pridopidine enhances autophagy, a cellular process critical to preserving neuronal health, and may reduce toxic protein aggregation associated with neurodegenerative diseases. The study also reveals the role of pridopidines mechanism of action in activating the S1R and facilitating the translocation of TFEB into the nucleus, leading to neuroprotection. Prilenia is focused on developing novel therapeutics for neurodegenerative and neurodevelopmental disorders and has received Fast Track designation for pridopidine for the treatment of HD. The company is backed by a group of investors including Forbion, Morningside, Sands Capital, SV Health Investors, Sectoral Asset Management, Talisman, Amplitude Ventures, and the ALS Investment Fund.","partners":null,"customers":null,"investors":["Forbion","Morningside","Sands Capital","SV Health Investors","Sectoral Asset Management","Talisman","Amplitude Ventures","ALS Investment Fund"],"confidence":9,"key_topics":["pridopidine","neuroprotective properties","autophagy","ALS","Huntingtons disease"],"date_of_event":"2022-05-25","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0WLzpSc1vTCCsMpRSyLQJBj3EOxsF5DWhect5JRNLuNcuvDp3vpIy4","news_summary":"Prilenia announces publication of data elucidating a mechanism for neuroprotective potential of pridopidine","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0f1CjDpl4tOti5rHMtlngwW5iq9USQWLp6iw2ZtxQWcXhyhcJkhvxq","date":"Apr 12, 2022","link":"https://www.businesswire.com/news/home/20220412005374/en/SV-Health-Investors-Joins-Prilenia-Series-B-as-the-Company-Prepares-for-ALS-and-HD-Data-Readouts-in-the-Next-12-Months","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"aup7oHqlCji4qZJMI8XY3c7AEyFtDwMC8x4KTbdqSOqYNwYU5dML7K","news_summary":"SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"957fe445-c5ff-460f-9973-0e6c305f2272","date":"Nov 4, 2021","link":"https://www.finsmes.com/2021/11/prilenia-therapeutics-raises-43m-in-series-b-funding.html","source":"www.finsmes.com","visible":1,"analysis":{"tags":"Series B Funding","company":"Prilenia Therapeutics","layoffs":null,"summary":"Prilenia Therapeutics, a biotech company, has raised $43M in Series B funding. The funding brings the total capital raised since its founding to $133.5M. The company plans to use the funds to prepare for potential registration and commercialization of its lead drug candidate, pridopidine, for patients with Huntingtons Disease and Amyotrophic Lateral Sclerosis. Pridopidine is a Phase 3 clinical stage drug candidate that is being assessed for the treatment of HD and ALS. The funding round was led by Sands Capital with participation from Forbion and Morningside, among others.","partners":null,"customers":null,"investors":"Sands Capital, Forbion, Morningside, Amplitude Ventures, Sectoral Asset Management, Talisman, ALS Investment Fund","confidence":9,"key_topics":["Prilenia Therapeutics","Series B Funding","neurodegenerative and neurodevelopmental disorders","pridopidine","Huntingtons Disease (HD) and Amyotrophic Lateral Sclerosis (ALS)"],"date_of_event":"04/11/2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$43M","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pYrNPEmVgUYnSKYAEC3mx7zj3JuspagRCs0PHmCK01l5qfbuEyGsIE","news_summary":"Prilenia Therapeutics Raises $43M in Series B Funding - FinSMEs","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"14d848b9-5beb-4e8a-9732-8546f38c78e6","date":"Jan 28, 2021","link":"https://www.businesswire.com/news/home/20210128005105/en/Prilenia-Enrolls-First-Subject-in-Europe-in-its-PROOF-HD-Phase-3-Clinical-Trial-for-Huntington%E2%80%99s-Disease","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"8ILJgOMurltlhTzgslmHJmwwqLyLhkEcqKcUXflXQdyEdQJ3s1DGS4","news_summary":"Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington's Disease","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c24c2d9d-3b9a-4269-aaf3-2a4439ff8ed0","date":"Jan 8, 2021","link":"https://www.businesswire.com/news/home/20210108005179/en/Prilenia-Announces-First-Patient-Enrolled-for-Pridopidine-Phase-23-Platform-Trial-for-ALS","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"GK5tQ9TSIGUDx6F2PmnGhCSUtJwM966GXs9TGEh4SQxLeSvyaMxCch","news_summary":"Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"851ab6fc-c95b-4274-8f66-23ccc3f3d0b7","date":"Oct 27, 2020","link":"https://www.businesswire.com/news/home/20201027005575/en/Prilenia-Enrolls-First-Patients-Into-its-PROOF-HD-Phase-3-Clinical-Trial-for-Huntington%E2%80%99s-Disease-in-the-United-States","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"USPeCIZtocymevpnWo3xdXwWbbcpZzMBs41TWcJewWHwqFbJ1mhuEv","news_summary":"Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington's Disease in the United States","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"6ccb269e-dee3-4327-a3dd-c30add55198e","date":"Jun 3, 2020","link":"https://en.globes.co.il/en/article-prilenia-therapeutics-raises-625m-names-michael-hayden-ceo-1001331202","source":"en.globes.co.il","visible":1,"analysis":{"tags":"biotech, financing","company":"Prilenia Therapeutics","layoffs":null,"summary":"Prilenia Therapeutics, a clinical stage biotech company, has raised $62.5 million in a Series A financing round. The funds will be used for two late-stage trials of pridopidine for the treatment of Huntingtons Disease (HD) and Amyotrophic Lateral Sclerosis (ALS). The company has also appointed Dr. Michael R. Hayden as CEO. The trials are expected to commence in the second half of 2020. Prilenia has raised a total of $84.5 million since its founding in 2018.","partners":null,"customers":null,"investors":["Forbion","Morningside Venture Investments","Sectoral Asset Management","Talisman Capital Partners","Genworks 2"],"confidence":9,"key_topics":["late-stage trials","pridopidine","ALS","HD","CEO appointment"],"date_of_event":"2020-06-03","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":62500000,"structured_issues":["Investment","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4rvnfO5dWSpIMj9wKXiIgsi0NJJ2MIsVn26J0Z7SPSrtSMXVg9KhKE","news_summary":"Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d7d67af1-0a2b-44de-be76-3b7137851d47","date":"Sep 8, 2019","link":"https://www.businesswire.com/news/home/20190918005530/en/Prilenia%E2%80%99s-Pridopidine-Chosen-Participate-ALS-Platform-Trial","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"JByF6SMk2sLjC3Gu7HGul8ukXvJys2opBlumKWXIAbvgEHgAFiWQyC","news_summary":"Prilenia's Pridopidine Chosen to Participate in the First ALS Platform Trial","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":11,"techcommunityinvolvement":null,"mediagallery":[{"id":"n0kPl6C0h73x3GTMiaj2PDTeXAiA03pngjH4qcTcEFIL3skYXEMbwu","timestamp":"2024-03-26 17:29:31.000000","resources_type":2,"resources_title":"Pridopidine Mechanism of Action","resources_file_name":"oFAMEbSEJZk","alt":"Pridopidine Mechanism of Action logo","imageurl":"https://img.youtube.com/vi/oFAMEbSEJZk/0.jpg","url":"http://youtu.be/oFAMEbSEJZk"}],"tags":["drug-development","pharmaceuticals","neurology","amyotrophic-lateral-sclerosis-(als)","biotechnology","parkinson","degenerative-diseases"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["Pridopidine"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":9,"lastfunding":"$11M","totalrounds":4,"fundingstage":"B","totalfunding":"$144.5M","publicinvestors":9,"lastpublicfunding":11000000,"totalpublicrounds":4,"totalpublicfunding":144500000},"team":[{"name":"Michael Hayden","email":"info@prilenia.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4P6nlYoJDA","bounced":false,"claimed":0,"founder":0,"urlname":"michael-hayden","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDggcOEhwkM","position":"CEO","last_name":"Hayden","claimtoken":"DZHbitPFG2d0aB5rDFxjXL9KRW0bQzpcXa4fS1sjZO73HmJXEsWU7s","first_name":"Michael","picturekey":"$fvUvy5jpmMYBrwAcEKwpWBfU0n18fEyfecijQ7A4q9C8jh3h75ag8b.jpeg","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dr-michael-hayden-mbchb-phd-7a303b153/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-08-29 12:46:33.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$fvUvy5jpmMYBrwAcEKwpWBfU0n18fEyfecijQ7A4q9C8jh3h75ag8b.jpeg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Limor Ben Har","email":"info@prilenia.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4P7Ck5ULDA","bounced":false,"claimed":0,"founder":0,"urlname":"limor-ben-har","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgwcCg5wkM","position":"COO","last_name":"Ben Har","claimtoken":"1ee1p6L7XdYb30BD3SZKzGr95MDGdv2ANRasrG8Kt7Xo2hYPhNOjrc","first_name":"Limor","picturekey":"$nDAa1Dx6PaPwAOzTNjSTyIEwmQbGe21XixUCorIsirzXEdWiMKbUPf.jpeg","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/limorbenhar/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-08-29 12:46:36.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$nDAa1Dx6PaPwAOzTNjSTyIEwmQbGe21XixUCorIsirzXEdWiMKbUPf.jpeg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Anne Sullivan","email":"info@prilenia.com","phone":"","gender":"Female","userid":"17ZlgReUYt6YULoMoFZuQoiVSbU6AYDxIUy5TS1q61gxrJahSph7bA","bounced":false,"claimed":null,"founder":0,"urlname":"anne-sullivan","visible":1,"memberid":"fFiytk7w5OE3KEdLU7xYwmhAXvKhI6B3An15sN6lSHIW8TSeDVhlTu","position":"Chief Business Officer","last_name":"Sullivan","claimtoken":null,"first_name":"Anne","picturekey":"$LBBUfCNpUuN8BtXyTwAAjkxa6cLI2TUDLaAbwNCvvz9r0bauK3KzVY.jpeg","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/anne-sullivan-4160112/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$LBBUfCNpUuN8BtXyTwAAjkxa6cLI2TUDLaAbwNCvvz9r0bauK3KzVY.jpeg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Henk Schuring","email":"info@prilenia.com","phone":"","gender":"Male","userid":"2wuMc2FLjMjddsE6ulUaUhZZTRl7PMqA50wRDvs9sbgqwDzie9ksWs","bounced":false,"claimed":null,"founder":0,"urlname":"henk-schuring","visible":1,"memberid":"I64txFRPFFSZXCM6W2fLr16OxH4PGbDWpxO4PXk6VMMBLQYPiymldq","position":"Chief Regulatory and Commercialization Officer","last_name":"Schuring","claimtoken":null,"first_name":"Henk","picturekey":"$RL15grWgFKRPYRotxRI5XeuvWboF83UaKzBka61YAlfL0LQW2Tlmdx.jpeg","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/henk-schuring-28a87019/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$RL15grWgFKRPYRotxRI5XeuvWboF83UaKzBka61YAlfL0LQW2Tlmdx.jpeg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yael Cohen","email":"info@prilenia.com","phone":"","gender":"Female","userid":"5M019PS0mqT6ybmUhYaFywtlftrDBpT1gOk5zyLQzUhxXfObaGqUXi","bounced":false,"claimed":null,"founder":0,"urlname":"yael-cohen-1","visible":1,"memberid":"0XOaJ83Vl1BUJvJaBMSV7w8r0MJzAmCgWy0hUJURgjsCyNg3INS4C0","position":"SVP, Head of Clinical Operations","last_name":"Cohen","claimtoken":null,"first_name":"Yael","picturekey":"$alazSOkssqB03ebOc89O2fmgRETMQk90Jbn3ZTmYpuG1hXgbT2p5TB.jpeg","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yael-cohen-2a38351a5/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$alazSOkssqB03ebOc89O2fmgRETMQk90Jbn3ZTmYpuG1hXgbT2p5TB.jpeg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Elena Berelovich","email":"info@prilenia.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4P6n84sIDA","bounced":false,"claimed":0,"founder":0,"urlname":"elena-berelovich","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg_qfv6goM","position":"VP & Head of CMC","last_name":"Berelovich","claimtoken":"xUX0Iw2by4TfXf2lkm2YMBEpojT0Z6YXUVtW3qazH5qRdbC5uzVcLP","first_name":"Elena","picturekey":"$UaZj46mlkCcrJ9RRBI0ffCB0v9rrjhh3EopMAMDxcEUFzJI2745l49.jpeg","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/elena-berelovich-38bba285/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-08-29 12:46:44.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$UaZj46mlkCcrJ9RRBI0ffCB0v9rrjhh3EopMAMDxcEUFzJI2745l49.jpeg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Michal Geva","email":"info@prilenia.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4N6zu5cLDA","bounced":false,"claimed":0,"founder":0,"urlname":"michal-geva-3","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg_rW9kAsM","position":"Head of Non-Clinical Development","last_name":"Geva","claimtoken":"DEQF2n1dmYlYuCvZZrNOarsWWpyWGbMnnfGRzzSa5q5cWejzrvyb8L","first_name":"Michal","picturekey":"$KvuGRTU6yGFolfgWcG8v2aX3OA6LbCmyzBEFGeh6vkAwAccQiaK81j.jpeg","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/michal-geva-6022a042/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-08-29 12:46:41.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$KvuGRTU6yGFolfgWcG8v2aX3OA6LbCmyzBEFGeh6vkAwAccQiaK81j.jpeg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Corporate Comms ","email":"info@prilenia.com","phone":"","gender":"Male","userid":"WkH6732feH6ToVbGwE6Fl3UaPeY2nb5Fdry8hz5dfwVe9GI7s7MMVU","bounced":false,"claimed":1,"founder":0,"urlname":"rob-cohen","visible":0,"memberid":"xzKWwhduDblJ1hvlnLoHmPzHqzdLkIYXEi29UbDUsW5hnv0X9hSDL8","position":"","last_name":"Comms ","claimtoken":"4CoqRkCqMhgJ27CGbExTu7gWiESh68Hg31B4dz187jiVZOBvzazBBT","first_name":"Corporate","picturekey":null,"claimeddate":"2024-03-27","linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-03-27 06:29:50.000000","initials":"CC","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>private</text>\n</div>'"}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2020-06-07T00:00:00.000Z","crunchbaseid":"prilenia","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2020-06-04T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"vrxqvuQn0UJvFU2ZcOHNkiXFGU3NCYxg0PJsxI5KfHC3AB40UiCjEA","date":"Apr 2022","amount":"$11M","source":"https://www.businesswire.com/news/home/20220412005374/en/SV-Health-Investors-Joins-Prilenia-Series-B-as-the-Company-Prepares-for-ALS-and-HD-Data-Readouts-in-the-Next-12-Months","eventtype":"FundingRoundEvent","investment":[{"name":"SV Health Investors","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/sv-health-investors","logokey":"$H6cIN6ACyeK4YopXKtC7lgzee3TvMZdNvWivwZPcOyYrIXduYeZKv5","tagline":"","urlname":"/investor_page/sv-health-investors","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkutiJCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Ar5Q5BWGJwet6xe3w5BTlegvbm5If6ztn9c0pk6LY2EyJX47UpTO94","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$H6cIN6ACyeK4YopXKtC7lgzee3TvMZdNvWivwZPcOyYrIXduYeZKv5","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Talisman Capital Partners","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/talisman-capital-partners","logokey":"$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","tagline":"","urlname":"/investor_page/talisman-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC-w-jWCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"B75gJoGeclTTg7HPlRa47DnQhgCX9JeD5aGKXlsbc4kbyRu3HJCji3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Sectoral Asset Management","type":"Investor","amount":null,"hidden":false,"country":"Canada","fullurl":"/investor_page/sectoral-asset-management","logokey":"$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","tagline":"","urlname":"/investor_page/sectoral-asset-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCB_5D_Cgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"b42jO8xsfCU3EDtFq3PrlYcK3H9pGS5xTfDnmEfYGwteQslfXNRDBy","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Amplitude Ventures","type":"Investor","amount":null,"hidden":false,"country":"Canada","fullurl":"/investor_page/amplitude-ventures","logokey":"$DjY7MLAZRGB7SqWamFf2nX6o11VZJNHvKUdZ0V8sqJdkudNLN1ZBWq","tagline":"","urlname":"/investor_page/amplitude-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDw4Z-ECQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cMpjXkXIFG7zQiol287AmRTwpohs4y0dOd9pCRtsplma2rseZb21RS","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DjY7MLAZRGB7SqWamFf2nX6o11VZJNHvKUdZ0V8sqJdkudNLN1ZBWq","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Morningside Venture Investments","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/morningside-venture-investments","logokey":"$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","tagline":"","urlname":"/investor_page/morningside-venture-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD-9YyZCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"eSGFMPOIDT1cyQn36En29QHXozY3WH4rIpHotXMi7GHuEgpu2OrSkT","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Forbion Capital Partners","type":"Investor","amount":null,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/forbion-capital-partners","logokey":"$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","tagline":"","urlname":"/investor_page/forbion-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEzfzOCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"fzBbfgmVlMLtclyhfpzd0PWYuxthXMzeWWd23Mf5MrL3A6HNT9RgZR","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Sands Capital","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/sands-capital","logokey":"$QOkt9HpUhhZetwb8f0MbuNlUQk0F543InyBTIOzXdHWib4HjmoURHU","tagline":"","urlname":"/investor_page/sands-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCQ_t6RCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"kSV2LlzvkjcWCHgiOvioT9UQEdSetgL1UQUyU4Ommgp1elJZBO07qx","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$QOkt9HpUhhZetwb8f0MbuNlUQk0F543InyBTIOzXdHWib4HjmoURHU","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":11000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCovsa5Cww","date":"Nov 2021","amount":"$43M","source":"https://www.finsmes.com/2021/11/prilenia-therapeutics-raises-43m-in-series-b-funding.html","eventtype":"FundingRoundEvent","investment":[{"name":"Amplitude Ventures","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/amplitude-ventures","logokey":"$DjY7MLAZRGB7SqWamFf2nX6o11VZJNHvKUdZ0V8sqJdkudNLN1ZBWq","tagline":"","urlname":"/investor_page/amplitude-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDw4Z-ECQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"012aaf2d-5297-43b7-beb8-36e3781596f4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DjY7MLAZRGB7SqWamFf2nX6o11VZJNHvKUdZ0V8sqJdkudNLN1ZBWq","leadcaption":"","followupcaption":""},{"name":"Morningside Venture Investments","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/morningside-venture-investments","logokey":"$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","tagline":"","urlname":"/investor_page/morningside-venture-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD-9YyZCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"44fcce4a-eac6-406f-82f9-ab25d32f12f8","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Talisman Capital Partners","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/talisman-capital-partners","logokey":"$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","tagline":"","urlname":"/investor_page/talisman-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC-w-jWCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4d5bd81f-0d4b-4801-a5ee-f249de5dcb79","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"ALS Investment Fund","type":"Holding Company","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/company_page/als-investment-fund","logokey":"$Kp1WRAmA4pfgBFicxHri27Mw4J6f1d69UMQzcfvkH9VFtwh7BSDiww","tagline":"","urlname":"/company_page/als-investment-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDw4Z-ECww","fundingtype":"Holding Company","leadpartner":null,"investmentid":"a9bfcda2-d9f2-4de0-b316-404aa87e81f0","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Kp1WRAmA4pfgBFicxHri27Mw4J6f1d69UMQzcfvkH9VFtwh7BSDiww","leadcaption":"","followupcaption":""},{"name":"Sectoral Asset Management","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/sectoral-asset-management","logokey":"$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","tagline":"","urlname":"/investor_page/sectoral-asset-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCB_5D_Cgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"b60fb18c-fb7b-432a-b0af-d53daf281208","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Sands Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/sands-capital","logokey":"$QOkt9HpUhhZetwb8f0MbuNlUQk0F543InyBTIOzXdHWib4HjmoURHU","tagline":"","urlname":"/investor_page/sands-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCQ_t6RCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"b819176a-ae7e-411b-93ac-1cd9e9d6d947","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$QOkt9HpUhhZetwb8f0MbuNlUQk0F543InyBTIOzXdHWib4HjmoURHU","leadcaption":"","followupcaption":""},{"name":"Forbion Capital Partners","type":"Investor","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/forbion-capital-partners","logokey":"$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","tagline":"","urlname":"/investor_page/forbion-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEzfzOCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"df982162-4041-4bd2-ac05-abb6dc89c099","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":43000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCBkcTPCww","date":"Jun 2020","amount":"$68.5M","source":"https://en.globes.co.il/en/article-prilenia-therapeutics-raises-625m-names-michael-hayden-ceo-1001331202","eventtype":"FundingRoundEvent","investment":[{"name":"Forbion Capital Partners","type":"Investor","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/forbion-capital-partners","logokey":"$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","tagline":"","urlname":"/investor_page/forbion-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEzfzOCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c5aecdcd-4b56-4078-a5e7-ee4960e0be3c","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","leadcaption":"Lead&nbsp;","followupcaption":""},{"name":"Sectoral Asset Management","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/sectoral-asset-management","logokey":"$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","tagline":"","urlname":"/investor_page/sectoral-asset-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCB_5D_Cgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bf5ddc60-fef1-45f9-832e-f9b061cb3a26","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","leadcaption":"","followupcaption":""},{"name":"Morningside Venture Investments","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/morningside-venture-investments","logokey":"$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","tagline":"","urlname":"/investor_page/morningside-venture-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD-9YyZCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e5aa789e-1cd2-43c5-b411-6e0de42c2c2f","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","leadcaption":"","followupcaption":""},{"name":"Talisman Capital Partners","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/talisman-capital-partners","logokey":"$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","tagline":"","urlname":"/investor_page/talisman-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC-w-jWCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"f6592772-6707-4901-832f-ac4916387fa4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":68500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD9tIniCQw","date":"May 2018","amount":"$22M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9b4e3d47-4821-43a7-93d6-2176a7b8e6b8","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":22000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"5/2018","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Prilenia Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$iBDdqS5peD0NxCANlMyQe0kfRmkIp3vXnBbMTgddyAf25zpK173jEG","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$iBDdqS5peD0NxCANlMyQe0kfRmkIp3vXnBbMTgddyAf25zpK173jEG","seoabout":"Prilenia is a late clinical-stage biotechnology company founded in 2018 focused on the urgent mission to develop novel therapeutics to address the progress...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":8,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Biotechnology","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"},{"title":"Pharmaceuticals","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Biotechnology","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"vrxqvuQn0UJvFU2ZcOHNkiXFGU3NCYxg0PJsxI5KfHC3AB40UiCjEA","date":"Apr 2022","amount":"$11M","source":"https://www.businesswire.com/news/home/20220412005374/en/SV-Health-Investors-Joins-Prilenia-Series-B-as-the-Company-Prepares-for-ALS-and-HD-Data-Readouts-in-the-Next-12-Months","eventtype":"FundingRoundEvent","investment":[{"name":"SV Health Investors","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/sv-health-investors","logokey":"$H6cIN6ACyeK4YopXKtC7lgzee3TvMZdNvWivwZPcOyYrIXduYeZKv5","tagline":"","urlname":"/investor_page/sv-health-investors","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkutiJCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Ar5Q5BWGJwet6xe3w5BTlegvbm5If6ztn9c0pk6LY2EyJX47UpTO94","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$H6cIN6ACyeK4YopXKtC7lgzee3TvMZdNvWivwZPcOyYrIXduYeZKv5","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Talisman Capital Partners","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/talisman-capital-partners","logokey":"$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","tagline":"","urlname":"/investor_page/talisman-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC-w-jWCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"B75gJoGeclTTg7HPlRa47DnQhgCX9JeD5aGKXlsbc4kbyRu3HJCji3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Sectoral Asset Management","type":"Investor","amount":null,"hidden":false,"country":"Canada","fullurl":"/investor_page/sectoral-asset-management","logokey":"$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","tagline":"","urlname":"/investor_page/sectoral-asset-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCB_5D_Cgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"b42jO8xsfCU3EDtFq3PrlYcK3H9pGS5xTfDnmEfYGwteQslfXNRDBy","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Amplitude Ventures","type":"Investor","amount":null,"hidden":false,"country":"Canada","fullurl":"/investor_page/amplitude-ventures","logokey":"$DjY7MLAZRGB7SqWamFf2nX6o11VZJNHvKUdZ0V8sqJdkudNLN1ZBWq","tagline":"","urlname":"/investor_page/amplitude-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDw4Z-ECQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cMpjXkXIFG7zQiol287AmRTwpohs4y0dOd9pCRtsplma2rseZb21RS","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DjY7MLAZRGB7SqWamFf2nX6o11VZJNHvKUdZ0V8sqJdkudNLN1ZBWq","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Morningside Venture Investments","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/morningside-venture-investments","logokey":"$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","tagline":"","urlname":"/investor_page/morningside-venture-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD-9YyZCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"eSGFMPOIDT1cyQn36En29QHXozY3WH4rIpHotXMi7GHuEgpu2OrSkT","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Forbion Capital Partners","type":"Investor","amount":null,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/forbion-capital-partners","logokey":"$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","tagline":"","urlname":"/investor_page/forbion-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEzfzOCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"fzBbfgmVlMLtclyhfpzd0PWYuxthXMzeWWd23Mf5MrL3A6HNT9RgZR","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Sands Capital","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/sands-capital","logokey":"$QOkt9HpUhhZetwb8f0MbuNlUQk0F543InyBTIOzXdHWib4HjmoURHU","tagline":"","urlname":"/investor_page/sands-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCQ_t6RCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"kSV2LlzvkjcWCHgiOvioT9UQEdSetgL1UQUyU4Ommgp1elJZBO07qx","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$QOkt9HpUhhZetwb8f0MbuNlUQk0F543InyBTIOzXdHWib4HjmoURHU","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":11000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCovsa5Cww","date":"Nov 2021","amount":"$43M","source":"https://www.finsmes.com/2021/11/prilenia-therapeutics-raises-43m-in-series-b-funding.html","eventtype":"FundingRoundEvent","investment":[{"name":"Amplitude Ventures","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/amplitude-ventures","logokey":"$DjY7MLAZRGB7SqWamFf2nX6o11VZJNHvKUdZ0V8sqJdkudNLN1ZBWq","tagline":"","urlname":"/investor_page/amplitude-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDw4Z-ECQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"012aaf2d-5297-43b7-beb8-36e3781596f4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DjY7MLAZRGB7SqWamFf2nX6o11VZJNHvKUdZ0V8sqJdkudNLN1ZBWq","leadcaption":"","followupcaption":""},{"name":"Morningside Venture Investments","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/morningside-venture-investments","logokey":"$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","tagline":"","urlname":"/investor_page/morningside-venture-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD-9YyZCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"44fcce4a-eac6-406f-82f9-ab25d32f12f8","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Talisman Capital Partners","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/talisman-capital-partners","logokey":"$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","tagline":"","urlname":"/investor_page/talisman-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC-w-jWCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4d5bd81f-0d4b-4801-a5ee-f249de5dcb79","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"ALS Investment Fund","type":"Holding Company","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/company_page/als-investment-fund","logokey":"$Kp1WRAmA4pfgBFicxHri27Mw4J6f1d69UMQzcfvkH9VFtwh7BSDiww","tagline":"","urlname":"/company_page/als-investment-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDw4Z-ECww","fundingtype":"Holding Company","leadpartner":null,"investmentid":"a9bfcda2-d9f2-4de0-b316-404aa87e81f0","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Kp1WRAmA4pfgBFicxHri27Mw4J6f1d69UMQzcfvkH9VFtwh7BSDiww","leadcaption":"","followupcaption":""},{"name":"Sectoral Asset Management","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/sectoral-asset-management","logokey":"$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","tagline":"","urlname":"/investor_page/sectoral-asset-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCB_5D_Cgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"b60fb18c-fb7b-432a-b0af-d53daf281208","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","leadcaption":"","followupcaption":"Follow on&nbsp;"},{"name":"Sands Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/sands-capital","logokey":"$QOkt9HpUhhZetwb8f0MbuNlUQk0F543InyBTIOzXdHWib4HjmoURHU","tagline":"","urlname":"/investor_page/sands-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCQ_t6RCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"b819176a-ae7e-411b-93ac-1cd9e9d6d947","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$QOkt9HpUhhZetwb8f0MbuNlUQk0F543InyBTIOzXdHWib4HjmoURHU","leadcaption":"","followupcaption":""},{"name":"Forbion Capital Partners","type":"Investor","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/forbion-capital-partners","logokey":"$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","tagline":"","urlname":"/investor_page/forbion-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEzfzOCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"df982162-4041-4bd2-ac05-abb6dc89c099","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":43000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCBkcTPCww","date":"Jun 2020","amount":"$68.5M","source":"https://en.globes.co.il/en/article-prilenia-therapeutics-raises-625m-names-michael-hayden-ceo-1001331202","eventtype":"FundingRoundEvent","investment":[{"name":"Forbion Capital Partners","type":"Investor","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/forbion-capital-partners","logokey":"$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","tagline":"","urlname":"/investor_page/forbion-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEzfzOCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c5aecdcd-4b56-4078-a5e7-ee4960e0be3c","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$youN0XZ0dpvlh749MNjkgAfgB2f6NOzoEY4JpA9sozrYguzuqx6n16","leadcaption":"Lead&nbsp;","followupcaption":""},{"name":"Sectoral Asset Management","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/sectoral-asset-management","logokey":"$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","tagline":"","urlname":"/investor_page/sectoral-asset-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCB_5D_Cgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bf5ddc60-fef1-45f9-832e-f9b061cb3a26","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vKi0DOT9yYB00Jn95TOPb36yNwxk8AEczLuFZfbYvU6aGddzFkHdOJ","leadcaption":"","followupcaption":""},{"name":"Morningside Venture Investments","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/morningside-venture-investments","logokey":"$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","tagline":"","urlname":"/investor_page/morningside-venture-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD-9YyZCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e5aa789e-1cd2-43c5-b411-6e0de42c2c2f","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JCbxljZYBKfJBSXCKv7e1C59yylE2URsFbdJCS4QG0jcTtMGlubflX","leadcaption":"","followupcaption":""},{"name":"Talisman Capital Partners","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/talisman-capital-partners","logokey":"$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","tagline":"","urlname":"/investor_page/talisman-capital-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC-w-jWCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"f6592772-6707-4901-832f-ac4916387fa4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$98EokgLt97Ck9uXxdezcaE50wFI2vOIdjgRA2SWkQHWs1ZURb0R2pu","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":68500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD9tIniCQw","date":"May 2018","amount":"$22M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9b4e3d47-4821-43a7-93d6-2176a7b8e6b8","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":22000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}